BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30670749)

  • 1. Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
    Yee CH; Zheng Z; Shuman L; Yamashita H; Warrick JI; Wu XR; Raman JD; DeGraff DJ
    Sci Rep; 2019 Jan; 9(1):270. PubMed ID: 30670749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKM2 Is Essential for Bladder Cancer Growth and Maintenance.
    Xia Y; Wang X; Liu Y; Shapiro E; Lepor H; Tang MS; Sun TT; Wu XR
    Cancer Res; 2022 Feb; 82(4):571-585. PubMed ID: 34903602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.
    Reddy OL; Cates JM; Gellert LL; Crist HS; Yang Z; Yamashita H; Taylor JA; Smith JA; Chang SS; Cookson MS; You C; Barocas DA; Grabowska MM; Ye F; Wu XR; Yi Y; Matusik RJ; Kaestner KH; Clark PE; DeGraff DJ
    Am J Pathol; 2015 May; 185(5):1385-95. PubMed ID: 25907831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.
    He F; Melamed J; Tang MS; Huang C; Wu XR
    Cancer Res; 2015 May; 75(10):2017-28. PubMed ID: 25795707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
    DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
    PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preneoplastic lesions and precursors of urothelial cancer].
    Knüchel-Clarke R; Gaisa NT
    Pathologe; 2016 Feb; 37(1):33-9. PubMed ID: 26811248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology of urothelial tumorigenesis: insights from genetically engineered mice.
    Wu XR
    Cancer Metastasis Rev; 2009 Dec; 28(3-4):281-90. PubMed ID: 20012171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth.
    Cheng J; Huang H; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
    Cancer Res; 2002 Jul; 62(14):4157-63. PubMed ID: 12124355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.
    Theodorescu D; Cornil I; Fernandez BJ; Kerbel RS
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):9047-51. PubMed ID: 2247480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
    Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
    Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.
    Tsuruta H; Kishimoto H; Sasaki T; Horie Y; Natsui M; Shibata Y; Hamada K; Yajima N; Kawahara K; Sasaki M; Tsuchiya N; Enomoto K; Mak TW; Nakano T; Habuchi T; Suzuki A
    Cancer Res; 2006 Sep; 66(17):8389-96. PubMed ID: 16951148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.
    Osei-Amponsa V; Buckwalter JM; Shuman L; Zheng Z; Yamashita H; Walter V; Wildermuth T; Ellis-Mohl J; Liu C; Warrick JI; Shantz LM; Feehan RP; Al-Ahmadie H; Mendelsohn C; Raman JD; Kaestner KH; Wu XR; DeGraff DJ
    Oncogene; 2020 Feb; 39(6):1302-1317. PubMed ID: 31636388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.
    Zhang ZT; Pak J; Huang HY; Shapiro E; Sun TT; Pellicer A; Wu XR
    Oncogene; 2001 Apr; 20(16):1973-80. PubMed ID: 11360181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and molecular markers of urothelial premalignancy and malignancy.
    Cordon-Cardo C; Cote RJ; Sauter G
    Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
    Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
    Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
    Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder.
    Oda S; Fujisawa M; Chunning L; Ito T; Yamaguchi T; Yoshimura T; Matsukawa A
    PLoS One; 2021; 16(11):e0254289. PubMed ID: 34818323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.
    Yang X; La Rosa FG; Genova EE; Huber K; Schaack J; Degregori J; Serkova NJ; Li Y; Su LJ; Kessler E; Flaig TW
    PLoS One; 2013; 8(9):e74809. PubMed ID: 24058630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder.
    Kitahama K; Shigematsu Y; Amori G; Sugawara E; Yonese J; Shibahara J; Takeuchi K; Inamura K
    Am J Surg Pathol; 2024 Apr; 48(4):458-464. PubMed ID: 38145408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HRAS mutations are frequent in inverted urothelial neoplasms.
    McDaniel AS; Zhai Y; Cho KR; Dhanasekaran SM; Montgomery JS; Palapattu G; Siddiqui J; Morgan T; Alva A; Weizer A; Lee CT; Chinnaiyan AM; Quist MJ; Grasso CS; Tomlins SA; Mehra R
    Hum Pathol; 2014 Sep; 45(9):1957-65. PubMed ID: 25097040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.